Oncoinvent ASA Income Statement

Financials in millions NOK. Fiscal year is January - December.

Millions NOK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Operating Revenue	14.35	2.73	0.06	0.07
Other Revenue	5.64	5.37	5.73	6.22
Revenue	20	8.1	5.79	6.28
Revenue Growth (YoY)	245.35%	39.95%	-7.85%	-
Gross Profit	20	8.1	5.79	6.28
Selling, General & Admin	46.99	51.44	55.74	47.34
Other Operating Expenses	65.64	83.13	86.22	61.57
Operating Expenses	127.75	149.12	153.22	116.89
Operating Income	-107.76	-141.02	-147.43	-110.61
Interest Expense	-	-0.08	-0.01	-0.01
Interest & Investment Income	1.47	1.34	4.41	4.44
Currency Exchange Gain (Loss)	-0.45	-0.45	-0.6	-0.11
Pretax Income	-106.73	-140.2	-143.62	-106.28
Net Income	-106.73	-140.2	-143.62	-106.28
Net Income to Common	-106.73	-140.2	-143.62	-106.28
Shares Outstanding (Basic)	127	92	19	19
Shares Outstanding (Diluted)	127	92	19	19
Shares Change (YoY)	555.68%	374.39%	0.27%	-
EPS (Basic)	-0.84	-1.52	-7.39	-5.48
EPS (Diluted)	-0.84	-1.52	-7.39	-5.48
Free Cash Flow	-85.6	-89.75	-164.94	-93.17
Free Cash Flow Per Share	-0.67	-0.97	-8.48	-4.80
Gross Margin	100.00%	100.00%	100.00%	100.00%
Operating Margin	-538.89%	-1740.31%	-2546.20%	-1760.48%
Profit Margin	-533.74%	-1730.24%	-2480.50%	-1691.55%
Free Cash Flow Margin	-428.09%	-1107.55%	-2848.72%	-1482.94%
EBITDA	-98.87	-131.81	-139.84	-105.82
D&A For EBITDA	8.89	9.2	7.59	4.79
EBIT	-107.76	-141.02	-147.43	-110.61
Revenue as Reported	20	8.1	5.79	6.28

Source: S&P Global Market Intelligence. Standard template. Financial Sources.